Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Jun 7, 2026, 9:21 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Hypertension
Interventions
Azilsartan medoxomil, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
413 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
60
States / cities
Alabaster, Alabama • Huntsville, Alabama • Tempe, Arizona + 57 more
Conditions
Hypertension
Interventions
aliskiren
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
671 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
East Hanover, New Jersey
Completed Not applicable Interventional Results available

HIRREM for Stage 1 Primary Hypertension

NCT03479697
Conditions
Hypertension, Blood Pressure, Cardiovascular Diseases, Cardiovascular Risk Factor, Autonomic Nervous System Imbalance
Interventions
HIRREM, Continued Current Care
Device · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Conditions
Essential Hypertension
Interventions
Azilsartan medoxomil and chlorthalidone, Azilsartan medoxomil and hydrochlorothiazide
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
609 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
50
States / cities
Birmingham, Alabama • Gulf Shores, Alabama • Scottsboro, Alabama + 47 more
Conditions
Insufficient Sleep, Hypertension
Interventions
Intervention
Behavioral
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
13 Years to 18 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Hypertension
Interventions
Azilsartan Medoxomil Low-dose, Losartan, Placebo for Azilsartan Medoxomil, Placebo for Losartan, Azilsartan Medoxomil Medium-dose (20 mg), Azilsartan Medoxomil High-dose (40 mg)
Drug
Lead sponsor
Arbor Pharmaceuticals, Inc.
Industry
Eligibility
6 Years to 18 Years
Enrollment
377 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
17
States / cities
Anaheim, California • Hialeah, Florida • Miami, Florida + 12 more
Conditions
Hypertension, Vascular Diseases, Cardiovascular Diseases
Interventions
Paradise Renal Denervation System, Renal Angiogram
Device · Procedure
Lead sponsor
ReCor Medical, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
28
States / cities
Birmingham, Alabama • Los Angeles, California • Bridgeport, Connecticut + 24 more
Conditions
HYPERTENSION, HYPERCHOLESTEROLEMIA
Interventions
valsartan + simvastatin
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 75 Years
Enrollment
369 participants
Timeline
Started 2004
U.S. locations
1
States / cities
East Hanover, New Jersey
Conditions
Osteoarthritis, Hypertension
Interventions
naproxcinod 375 mg -750 mg -1125 mg bid, naproxen 250 mg - 500mg -750 mg bid
Drug
Lead sponsor
NicOx
Industry
Eligibility
40 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
29
States / cities
Mobile, Alabama • Tempe, Arizona • Tucson, Arizona + 26 more
Conditions
Hypertension, Essential
Interventions
Candesartan cilexetil (Atacand), 4 mg, Candesartan cilexetil (Atacand), 8 mg, Nifedipine GITS (Adalat, BAYA1040), 20 mg, Nifedipine GITS (Adalat, BAYA1040), 30 mg, Nifedipine GITS (Adalat, BAYA1040), 60 mg, Placebo, Candesartan cilexetil (Atacand), 16 mg, Candesartan cilexetil (Atacand), 32 mg
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
1,381 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
23
States / cities
Mobile, Alabama • Los Angeles, California • Coral Gables, Florida + 18 more
Conditions
Essential Hypertension
Interventions
Lower leg heat therapy
Behavioral
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
60 Years to 85 Years · Female only
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Dallas, Texas
Conditions
Hypertension
Interventions
aliskiren
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
641 participants
Timeline
2005 – 2006
U.S. locations
1
States / cities
East Hanover, New Jersey
Active, not recruiting Not applicable Interventional Results available

A Study of the ReCor Medical Paradise System in Clinical Hypertension

NCT02649426
Conditions
Hypertension, Vascular Diseases
Interventions
The Paradise® Renal Denervation Ultrasound System, Sham Procedure
Device
Lead sponsor
ReCor Medical, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
24
States / cities
Birmingham, Alabama • Los Angeles, California • Sacramento, California + 18 more
Conditions
Hypertension,Essential
Interventions
Captopril Pill, Enalapril Pill, Hydrochlorothiazide
Drug
Lead sponsor
Penn State University
Other
Eligibility
40 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2022
U.S. locations
1
States / cities
University Park, Pennsylvania
Conditions
Hypertension
Interventions
Aliskiren, Ramipril, Hydrochlorothiazide, Amlodipine
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
65 Years and older
Enrollment
901 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
East Hanover, New Jersey
Conditions
Hypertension, Essential Hypertension
Interventions
Not listed
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
2 Years to 99 Years
Enrollment
2,300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2034
U.S. locations
1
States / cities
Bethesda, Maryland
Active, not recruiting Not applicable Interventional

RADIANCE Continued Access Protocol

NCT05017935
Conditions
Hypertension, Hypertension, Resistant to Conventional Therapy, Vascular Diseases, Cardiovascular Diseases
Interventions
Renal Denervation
Device
Lead sponsor
ReCor Medical, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
40
States / cities
Chula Vista, California • Los Angeles, California • Sacramento, California + 34 more
Conditions
Hypertension, Left Ventricular Hypertrophy, Overweight
Interventions
Aliskiren 150/300 mg, Losartan 50/100 mg, Aliskiren placebo, Losartan 50/100 mg placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
East Hanover, New Jersey
Conditions
Hypertension, Systolic, Cerebrovascular Disease
Interventions
Anti-hypertensive therapy to SBP 130 mm Hg, Anti-hypertensive therapy to SBP 145 mm Hg
Other
Lead sponsor
UConn Health
Other
Eligibility
75 Years and older
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Farmington, Connecticut
Conditions
Elevated Triglycerides, Systolic Hypertension, Insulin Resistance, Abdominal Obesity
Interventions
standard ADA diet, energy restricted very-low carbohydrate diet, low glycemic diet
Dietary Supplement
Lead sponsor
CAMC Health System
Other
Eligibility
12 Years to 18 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Charleston, West Virginia
Conditions
Diabetes Mellitus, Metabolic Syndrome, Obesity, Hypertension,Essential, Hyperlipidemias, Cardiovascular Diseases, Kidney Disease, Chronic
Interventions
Lifestyle Medicine Program, Medically Tailored Groceries
Behavioral
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 75 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Newark, New Jersey
Conditions
Hypertension
Interventions
Azilsartan medoxomil and olmesartan, Olmesartan, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
1,275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
80
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mesa, Arizona + 77 more
Conditions
Hypertension, Hypertension, Systolic, Hypertension, Essential
Interventions
Medtronic Astra/Azure DR MRI IPG with AVIM therapy Activated, Medtronic Astra/Azure DR MRI IPG with AVIM therapy Deactivated
Device
Lead sponsor
Orchestra BioMed, Inc
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
70
States / cities
Scottsdale, Arizona • Glendale, California • Newport Beach, California + 59 more
Conditions
Hypertension
Interventions
Olmesartan medoxomil, Olmesartan medoxomil/hydrochlorothiazide, Hydrochlorothiazide
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004
U.S. locations
16
States / cities
Fort Lauderdale, California • Long Beach, California • Roseville, California + 13 more